07.09.26 -- A Vaccine To Prevent Breast Cancer Recalibrates The Possible

Prepare for the upcoming USP <788> revisions by strengthening your particulate control strategy to support regulatory compliance, product quality, and patient safety across injectable drug products.

An optimized lyophilization cycle removes excess moisture during scale‑up by adjusting drying for larger equipment, improving stability, maintaining efficiency, and supporting clinical validation.

Data-driven virus clearance improves risk assessment, process insight, and study design. Learn how Quality by Design cuts late-stage risk while strengthening regulatory confidence and viral safety.

Integrated clinical supply links manufacturing and trials to improve speed, visibility, and compliance — shortening timelines and supporting consistent global execution.

Discover how an optimized, end-to-end development strategy can help sponsors reach key clinical milestones faster and bring potentially life-saving therapies to patients sooner.

Scale-out manufacturing speeds commercial launch by using modular single-use systems that preserve process consistency, reduce comparability risk, and align capacity with demand.

Automated optical inspection enhances injectable quality by improving detection accuracy, ensuring consistency, and enabling high-speed defect and container integrity checks.

Unlock significant lab efficiency and financial gains. See how focused optimization of workflows and asset management led to substantial cost savings and reclaimed six-figure value in consumables.

With increased pressure on CMC development to support shortened BLA submission timelines, mass spectrometry (MS) can be leveraged to accelerate and de-risk product and process development.

The pre-filled syringe space is one of the fastest growing pharma sectors, offering greater patient safety and lower manufacturing costs. But pre-filled doesn’t translate to easily filled; there are obstacles.

Lilith Baczynski highlights how the Fremont site’s scale, flexibility, and expert teams support global mammalian biologics manufacturing.

Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks.